| Literature DB >> 35250549 |
Jieke Liu1, Xi Yang1, Yong Li1, Hao Xu1, Jing Ren1, Peng Zhou1.
Abstract
OBJECTIVE: Arterial spin labeling (ASL) studies have revealed inconsistent regional cerebral blood flow (CBF) alterations in patients with type 2 diabetes mellitus (T2DM). The aim of this systematic review and meta-analysis was to identify concordant regional CBF alterations in T2DM.Entities:
Keywords: arterial spin labeling; cerebral blood flow; meta-analysis; seed-based d mapping; type 2 diabetes mellitus
Year: 2022 PMID: 35250549 PMCID: PMC8888831 DOI: 10.3389/fnagi.2022.847218
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
FIGURE 1PRISMA flow diagram for literature search and study selection. PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses; T2DM, type 2 diabetes mellitus; HCs, healthy controls; CBF, cerebral blood flow; ROI, region of interest.
Arterial spin labeling studies investigating cerebral blood flow alterations in patients with T2DM relative to healthy controls.
| References | T2DM | Healthy controls | Method | Brain regions | CBF alteration | |||
| No. (male/female) | Age | Comorbidity (No.) | No. (male/female) | Age (years) | ||||
|
| 26 (13/13) | 61.6 ± 6.6 | Hyperlipidemia (10), hypertension (10), retinopathy (10) | 25 (13/12) | 60.4 ± 8.6 | ROI | Frontal, temporal, and parieto-occipital lobe | ↓ |
|
| 61 (31/30) | 65 ± 8 | Hyperlipidemia (34), hypertension (38), peripheral neuropathy (31) | 67 (28/39) | 67 ± 9 | ROI | Cerebellum, frontal, temporal, parietal, and occipital lobe | n.s. |
|
| 15 (8/7) | 62.0 ± 7.9 | Hyperlipidemia (10) | 14 (4/10) | 60.1 ± 9.9 | VBA | Insular cortex | ↓ |
|
| 23 (9/14) | 54.2 ± 5.2 | NA | 37 (15/22) | 51.8 ± 3.8 | ROI | Frontal and parietal lobe | n.s. |
|
| 38 (17/21) | 56.0 ± 6.1 | Hypertension (29) | 40 (21/19) | 57.1 ± 7.6 | VBA | R middle occipital gyrus, R and L inferior parietal lobe, R precuneus | ↓ |
|
| 41 (NA) | NA | Hypertension (39), cardiovascular disease (8) | 39 (NA) | NA | ROI | Whole cerebral cortex, frontal, temporal, parietal, and occipital cortex, and subcortical gray matter | n.s. |
| VBA | n.s. | |||||||
|
| 40 (21/19) | 60.5 ± 6.9 | Lacunar infarcts (9) | 41 (13/28) | 57.9 ± 6.5 | VBA | Dorsal anterior cingulate cortex | ↑ |
| R and L middle occipital gyrus, R precuneus, cuneus | ↓ | |||||||
|
| 41 (19/22) | 65.5 ± 8.3 | Hypertension (32) | 32 (16/16) | 67.3 ± 10.1 | VBA | Cerebellum, frontal lobe | ↓ |
|
| 36 (17/19) | 57.6 ± 6.2 | Hyperlipidemia (9), hypertension (20), white matter hyperintensities (29) | 36 (14/22) | 56.2 ± 6.8 | VBA | n.s. | |
|
| 11 (8/3) | 72.3 ± 2.8 | Hypertension (11), cardiovascular disease (1), atrial fibrillation (1) | 38 (13/25) | 73.6 ± 5.9 | ROI | R and L hippocampus, R inferior parietal cortex, R inferior temporal cortex, R rostral middle frontal gyrus | ↓ |
| L inferior parietal cortex, L inferior temporal cortex, R and L medial orbitofrontal cortex, L rostral middle frontal gyrus | n.s. | |||||||
|
| 26 (10/16) | 51.9 ± 10.7 | Hyperlipidemia (9), hypertension (7), cardiovascular disease (1) | 26 (11/15) | 48.2 ± 6.7 | VBA | R temporopolar, R superior and middle frontal gyrus | ↑ |
|
| 18 (15/3) | 62.5 ± 3.7 | Hyperlipidemia (16), hypertension (9) | 15 (3/12) | 71.8 ± 6.1 | ROI | Global cortex, R and L cerebral, prefrontal, rostral anterior cingulate, precuneus/posterior cingulate, parietal, lateral temporal, mesial temporal, occipital, and sensorimotor cortex | ↓ |
|
| 31 (15/16) | 53.4 ± 9.1 | Retinopathy (31) | 33 (12/21) | 51.6 ± 9.8 | VBA | L middle temporal gyrus, R and L supplementary motor area | ↑ |
| R and L calcarine, and caudate | ↓ | |||||||
T2DM, type 2 diabetes mellitus; CBF, cerebral blood flow; ROI, region of interest; VBA, voxel-based analysis; NA, not available; R, right; L, left; n.s., no significant difference between T2DM and healthy controls; downward arrow (↓), decreased CBF in T2DM; upward arrow (↑), increased CBF in T2DM.
Clinical characteristics of the included studies in the meta-analysis.
| References | Education | Duration | Onset | BMI | HbAlc | MMSE |
|
| 9.6 ± 3.0 | 7.1 ± 3.5 | 48.9 | 24.4 ± 2.6 | 7.2 ± 1.1 | 29.0 ± 0.9 |
|
| NA | 9.8 ± 6.7 | NA | 29.2 ± 3.5 | 6.7 ± 0.4 | 28.6 ± 1.4 |
|
| 10.0 ± 3.4 | 8.9 ± 5.0 | 51.6 | 24.4 ± 2.7 | 7.7 ± 1.6 | 28.3 ± 1.0 |
|
| 15.4 ± 3.8 | 9.9 ± 7.9 | 55.6 | 29.1 ± 6.8 | 7.3 ± 1.25 | 28.6 ± 1.5 |
|
| 9.1 ± 1.5 | 5.4 ± 4.9 | 52.2 | 26.0 ± 2.9 | NA | NA |
|
| 10.3 ± 3.7 | 9.2 ± 7.1 | 42.7 | 24.0 ± 3.6 | NA | 26.9 ± 3.9 |
|
| NA | NA | NA | NA | 7.3 ± 1.4 | NA |
T2DM, type 2 diabetes mellitus; BMI, body mass index; HbA
Acquisition parameters and analytic methods of the included studies in the meta-analysis.
| References | Acquisition parameters | Analytic methods | |||||||
| Scanner | Sequence | Labeling duration (ms) | PLD (ms) | Resolution (mm) | Software | FWHM (mm) | PVE correction | Threshold | |
|
| 3T | PASL | 600 | 1000 | 3.4 × 3.4 × 4 | SPM8 | 6 | NA | Cluster-level FWE |
|
| 3T | PCASL | 1,650 | 1,525 | 3 × 3 × 7 | SPM8 | NA | NA | FDR |
|
| 3T | PASL | 600 | 1,000 | 3.4 × 3.4 × 4 | AFNI | 6 | GM + 0.4 × WM | AlphaSim |
|
| 3T | PCASL | 1,500 | 1,500 | 1.9 × 1.9 × 4 | SPM8 | 8 | Volume of GM | Cluster-level FWE |
|
| 3T | PASL | Multiple TI | 3.4 × 3.4 × 4 | SPM8 | NA | GM + 0.4 × WM | FDR | |
|
| 3T | PCASL | 1,525 | 1,525 | Thickness 4 | SPM8 | 8 | Volume of brain | AlphaSim |
|
| 3T | PCASL | 1,525 | 1,525 | Thickness 3.5 | SPM8 | 6 | NA | Gaussian random field |
PASL, pulsed arterial spin labeling; PCASL, pseudo-continuous arterial spin labeling; PLD, post labeling delay PLD; TI, inversion time; SPM, Statistical Parametric Mapping; AFNI, Analysis of Functional NeuroImages; FWHM, full width at half maximum; PVE, partial volume effect; GM, gray matter; WM, white matter; FWE, familywise error rate; FDR, false discovery rate; NA, not available.
*The labeling duration in PCASL is analogous to the bolus duration (TI1) in PASL.
**The PLD in PCASL is analogous to the difference between TI and TI1 in PASL.
***The Multiple TI includes 16 TIs from 480 to 4,080 ms with a step of 225 ms.
Differences in regional cerebral blood flow alterations between patients with T2DM and healthy controls.
| MNI coordinates | SDM- | No. of voxels | Cluster breakdown (no. of voxels) | ||
|
| |||||
| R supplementary motor area | 6, –12, 68 | 1.320 | 0.0002 | 438 | R supplementary motor area (273) |
|
| |||||
| L middle occipital gyrus | –18, –94, –2 | –1.543 | 0.0004 | 822 | L middle occipital gyrus (337) |
| R middle occipital gyrus | 30, –90, 10 | –1.380 | 0.0010 | 309 | R middle occipital gyrus (194) |
| L caudate nucleus | –12, –2, 18 | –1.365 | 0.0011 | 53 | L caudate nucleus (48) |
| R superior parietal gyrus | 16, –64, 56 | –1.201 | 0.0023 | 54 | R superior parietal gyrus (44) |
| L calcarine fissure/surrounding cortex | 2, –86, 8 | –1.227 | 0.0021 | 52 | L calcarine fissure/surrounding cortex (45) |
T2DM, type 2 diabetes mellitus; MNI, Montreal Neurological Institute; SDM, seed-based d mapping; R, right; L, left.
FIGURE 2Voxel-based meta-analysis results of regions with cerebral perfusion alterations in T2DM. (A) Red region indicates increased CBF in patients with T2DM compared with healthy controls. (B–D) Blue regions indicate decreased CBF in patients with T2DM compared with healthy controls. T2DM, type 2 diabetes mellitus; CBF, cerebral blood flow; R, right; L, left.